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Abstract
Introduction The amounts of estrogen receptor (ER) and
progesterone receptor (PgR) in a primary tumor are predictive of
the response to endocrine therapies of breast cancer. Several
patients with ER-positive primary tumors relapse after adjuvant
endocrine therapy with no ER expression in the recurrent tissue;
much fewer with a recurrent disease after an ER-negative
primary tumor may become endocrine responsive. These
sequences of events indicate that a phenotype based on ER
expression may not be a permanent feature of breast cancer.
Methods Ten patients with advanced breast cancer whose
tumors overexpressed HER-2, but not ER or PgR, were treated
with weekly trastuzumab at standard doses with or without
chemotherapy.
Results Three out of 10 patients showed overexpression of ERs
first appearing after 9, 12 and 37 weeks, respectively, from the
initiation of trastuzumab. Two of these patients were
subsequently treated with endocrine therapy alone: one of them
received letrozole for 3 years without evidence of progression.
Conclusion Therapeutic targets enabling the appearance of an
endocrine responsive disease may increase treatment options
for patients with breast cancer. Furthermore, these clinical data
suggest that an ER-negative phenotype is a multi-step process
with a reversible repression modality, and that some ER-
negative tumors may either revert to an ER-positive phenotype,
allowing an endocrine treatment to be effective.
Introduction
Biological features of endocrine responsiveness, namely the
overexpression of estrogen receptor (ER) and/or progester-
one receptor (PgR), are important predictive and prognostic
markers in breast cancers [1]. About 50% of patients with ER-
positive primary tumors that relapse after adjuvant tamoxifen
therapy have recurrent tumors in which ER expression is lost
[2]. Progression to an ER-negative phenotype typically
involves the constitutive overexpression of growth-promoting
genes that are normally regulated by estrogens, thereby lead-
ing to a loss of estrogen dependence, resistance to anti-estro-
gens, and a more aggressive phenotype overall.
The re-expression of ER in tumors in which ER has been lost
or is not expressed could therefore indicate sensitivity to endo-
crine therapy. ER-negative tumors frequently overexpress
growth factor receptors such as epidermal growth factor
receptor (EGFR) or c-erbB2 [3,4], as do many ER-negative
breast cancer cell lines, suggesting that upregulated growth
factor signaling might provide an alternative growth stimulus.
The overexpression of EGFR and c-erbB2 is also an important
prognostic indicator of breast cancer, independently of their
inverse correlation with ER expression [5,6]. This increased
expression and/or activation of growth factor receptors corre-
lates with increased mitogen-activated protein kinase (MAPK)
activity, both in tumors and in cell lines [7-9]. Using cell lines
EGFR = epidermal growth factor receptor; ER = estrogen receptor; ERK = extracellular signal-regulated kinase; MAPK = mitogen-activated protein 
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that overexpress constitutively active forms of Raf-1, MAPK/
ERK kinase (MEK)-1, or c-erbB-2 and ligand-activatable
EGFR, some authors have shown that the resultant hyperacti-
vation of MAPK (ERK1/2) activity through these signaling
pathways leads to the downregulation of ERα. This downreg-
ulation is not a consequence of ligand-independent ERα acti-
vation and is reversible in vitro. Abrogation of ERK
(extracellular signal-regulated kinase) activity with the use of
either pharmacologic inhibitors or dominant-negative ERK
constructs reverses the downregulation of ERα and restores
its activity [10]. These data suggest that upregulated growth
factor signaling via MAPK is directly linked to the loss of ER
expression and generation of the ER-negative phenotype and
that, at some stage in the progression pathway, the ER-nega-
tive phenotype may be not permanent.
As a consequence, therapeutic targets enabling the restora-
tion of ER expression may provide beneficial treatment strate-
gies for breast cancer patients.
Both gefitinib (Iressa®), which inhibits the kinase activity of
EGFR, and trastuzumab (Herceptin™), a monoclonal antibody
against c-erbB2, have been shown to reduce MAPK activity
[11].
These data support the hypothesis that a patient with
advanced breast cancer with ER-negative tumors and c-erbB2
overexpressed could revert from an ER-negative phenotype to
ER-positive after treatment with trastuzumab.
Methods
From August 1999 to November 2002, 10 patients with
advanced breast cancer whose tumors overexpressed HER-2
(defined as a HercepTest score of 3+; Dako, Carpinteria, CA,
USA), and with both ER and PgR negative were treated with
weekly trastuzumab (Herceptin; Hoffman La-Roche, Basel,
Switzerland) at a weekly dosage of 2 mg/kg intravenously
(after an initial loading dose of 4 mg/kg) plus chemotherapy.
Paclitaxel (Taxol®; Bristol-Myers Squibb Company, Princeton,
NJ, USA) at a weekly dosage of 90 mg/m2 intravenously, for
three consecutive weeks every 4 weeks, was given to nine
patients; the tenth patient received vinorelbine (Navelbine®;
Pierre Fabre Pharma-30, Pierre Fabre Medicament-F-2849) at
a weekly dosage of 20 mg/m2 per week intravenously, for three
consecutive weeks every 4 weeks.
Chemotherapy started concomitantly with trastuzumab in
seven patients and, after evidence of progression, to trastuzu-
mab alone in three patients. Tumor tissue for immunohisto-
chemical analysis was obtained from all patients at baseline
and after a median period of 9 weeks (range 3 to 37 weeks) of
treatment with trastuzumab, with or without chemotherapy. All
samples were processed and read in the same laboratory.
Basal evaluations were assessed on primary tumors in four
patients and on metastatic sites in six (skin in four patients,
pleura in one, liver in one). Tumor immunohistochemical reas-
sessment was performed on the primary tumor in one patient,
on the metastatic skin tissue in seven and on other metastatic
Table 1
Patients' characteristics
Patient Baseline evaluation After treatment
ER, 
%
PgR, 
%
HER2, % 
(score)
First 
assessment
Time A Chemotherapy Time B Second 
assessment
ER, 
%
PgR, 
%
HER2, % 
(score)
HT Clinical 
response
1 0 0 80 (3+) Skin 20 Paclitaxel 9 Skin 10 0 70 (3+) No PR
2 0 0 70 (3+) Pleura 87 Paclitaxel 11 Pleura 0 0 75 (3+) No SD
3 0 0 90 (3+) Skin 8 Nonea 4 Skin 0 0 90 (3+) No PR
4 0 0 40 (3+) Skin 31 Paclitaxel 9 Skin 0 0 90 (3+) No PD
5 0 0 90 (3+) Liver 5 Nonea 12 Ovary 50 40 80 (3+) Yes PD
6 0 0 95 (3+) Breast 2 Paclitaxel 37 Breast 20 0 90 (3+) Yes PR
7 0 0 80 (3+) Skin 64 Nonea 4 Skin 0 0 95 (3+) No PR
8 0 0 90 (3+) Lung 2 Paclitaxel 4 Skin 0 0 90 (3+) No SD
9 0 0 80 (3+) Skin 51 Paclitaxel 22 Skin 0 0 40 (2+) No PR
10 0 0 90 (3+) Skin 17 Vinorelbine 3 Skin 0 0 90 (3+) No PR
The table shows the evaluation of patients' characteristics at baseline with the site of disease at which the biological characteristics were 
evaluated, and after treatment with trastuzumab with the site of disease at which the biological characteristics were reassessed. ER, estrogen 
receptor; first assessment, site of disease where ER, PgR and HER2 were evaluated at baseline; HT, hormonal treatment; PgR, progesterone 
receptor; second assessment, site of disease where ER, PgR and HER2 were reassessed; time A, time elapsed between first assessment and 
treatment start (weeks); time B, time elapsed between trastuzumab start and second assessment (weeks). PD, progressive disease. SD, stable 
disease. PR, partial response.
aPaclitaxel was introduced after progression to trastuzumab alone.Available online http://breast-cancer-research.com/content/8/1/R4
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sites in the remaining two (pleura in one, ovary in one) (Table
1).
Response to treatment was assessed in accordance with
World Health Organization criteria.
The study protocol was reviewed and approved by the
research ethics committee of the study center and relevant
regulatory authorities. The study treatment was performed in
accordance with Good Clinical Practice and the Helsinki dec-
laration. Written informed consent was obtained from all
patients.
Results
We observed that 3 out of 10 patients had tumors that were
ER positive (at least 10% of cells) after the histologic reas-
sessment (see Table 1).
Patient 1 had a metastatic disease to bone, skin and liver and
had a partial response to trastuzumab and paclitaxel after 1
month. Two months after treatment start she had a skin biopsy
in the same site as baseline, with evidence of ER positivity
(10%). The response to the combination chemotherapy and
immunotherapy was maintained for 5 months. The patient was
subsequently treated with multiple cycles of chemotherapy
and died of progressive disease about 1 year later.
Patient 5 had metastatic disease to the liver and did not
respond to trastuzumab. After 2 months from the start of tras-
tuzumab treatment she underwent ovariectomy because of
progressive disease. The ER and PgR assessment on ovarian
metastases was positive (ER 50%; PgR 40%). Subsequently
she received trastuzumab and paclitaxel without any response,
and afterwards letrozole for 3 months with a progression to
CNS (central nervous system). The patient died 6 months
later.
Patient 6 underwent therapy with paclitaxel and trastuzumab
for a cutaneous and controlateral relapse and had a partial
response after 1 month of treatment. Seven months later she
underwent mastectomy with evidence of positive ER. Subse-
quently the patient received letrozole for 3 years without pro-
gression of disease. Recently, she had a subcutaneous
relapse that was biopsied and showed negative for ER and
PgR, with HER-2 overexpressed; she is currently being treated
with vinorelbine and trastuzumab.
In these three patients we observed the reversion of ER to a
positive phenotype after 9, 12 and 37 weeks, respectively,
from the start of treatment with trastuzumab. In two patients
(patients 1 and 6) trastuzumab was given concomitantly with
paclitaxel; the third (patient 5) had received trastuzumab alone
when ER re-expression was assessed.
Discussion
This is the first report of an ER-negative phenotype changing
to ER positive after a trastuzumab-containing therapy in
patients with advanced breast cancer. Interestingly, previous
reports evaluating the use of trastuzumab in the preoperative
setting in patients with locally advanced breast cancer do not
address this particular issue [12,13].
The patient sample was limited, but this could be an important
anecdoctal and hypothesis-generating report that should be
confirmed in larger trials.
Another potential limit was that the reassessment was per-
formed at a variable time point after the start of therapy, and
the timing was not predefined. Our three patients had a rever-
sion of ER to a positive phenotype after 9, 12 and 37 weeks
from the start of treatment with trastuzumab. For this reason
we do not have data on which to base a hypothesis about the
optimal timing for performing the reassessment.
A recent report by Arpino et al. proposed that a lack of PgR
expression could be a reflection of active signaling in the HER
family and, as a consequence, the response to trastuzumab
might be different in the PgR-positive and PgR-negative sub-
sets [14]. Interestingly, two of our patients after ER reversion
to a positive phenotype remained PgR negative; both had a
partial response to trastuzumab, whereas the only patient who
also had a PgR reversion was resistant to trastuzumab.
Other studies that address ER loss reversibility in breast can-
cer cell lines involve treatments with demethylating agents
such as 5-azacytidine [15,16]. About 25% of ER-negative
breast tumors were found to contain methylated ER [17].
However, several ER-positive tumors also showed similar
degrees of methylation [18]. Methylation, by modifying the
DNA structure assisting in the recruitment of histone deacety-
lases, ensures that the gene is in an inactive conformation. If
methylation occurs as a step subsequent to another mecha-
nism of ER repression, one would predict that some ER-nega-
tive breast tumors at an earlier point in a progression pathway
do not express ER because one of these other mechanisms is
still operative. In such tumors, it might then be possible to
reverse this phenotype and restore antiestrogen sensitivity,
perhaps by using a demethylating agent.
An interesting recently reported transcription factor that might
be linked to hormone-independent breast cancer, as well as
elevated growth factor signaling, is NF-κB. Its activity is ele-
vated in hormone-independent breast cancer, and it is impli-
cated in enhanced cell survival and chemoresistance in cancer
[19]. Holloway et al. have shown recently that an elevation in
NF-κB activity is attributable to enhanced growth factor sign-
aling through ERK1/2; inhibiting this NF-κB activity, either
pharmacologically or through the expression of a constitutively
active IκB, partly restores ER activity and expression in theseBreast Cancer Research    Vol 8 No 1    Munzone et al.
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cells. These findings suggest a role for cytoplasmic substrates
of MAPK in ER downregulation in breast cancer and further
support a role for MAPK-induced NF-κB activity in this down-
regulation [20].
Conclusion
We conclude that our clinical data – although limited in the
patient sample – support previous assessments in vitro, sug-
gesting that an ER-negative phenotype may be a multi-step
process with a reversible repression modality, and that some
ER-negative tumors might revert to the ER-positive phenotype
allowing an endocrine-based treatment.
Although further studies are essential to show that inhibitors of
mitogenic signaling can restore ER expression and/or function
in breast tumors, coupling molecules such as signal transduc-
tion inhibitors, monoclonal antibodies, demethylating agents
or NF-κB inhibitors with antiestrogens could result in therapies
that are better tolerated and active for the treatment of ER-
negative breast cancer. In addition, once the MAPK substrate
or substrates responsible for ER downregulation are identi-
fied, they could provide an additional drug target.
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